Hematology

Latest News

Despite the frequent potential for drug-drug interaction, exposure to CYP3A inducers or inhibitors was not linked to worse overall survival (OS) after adjusting for age, comorbidity, and dosing. | Image Credit: sovova - stock.adobe.com
Drug Interactions With Ibrutinib Common, Linked to Higher Infection Risk in CLL

September 16th 2025

Drug interactions with ibrutinib may not shorten survival when managed carefully, though the significant increase in infection-related hospitalizations tied to CYP3A inhibitors signals an urgent need for closer monitoring, dose adjustment, and proactive infection prevention strategies.

Lori A. Leslie, MD | Image: John A. Theurer Cancer Center
Phase 2 Study Shows Feasibility of Axi-Cel Delivery in Outpatient Setting

September 13th 2025

The iRR6 may help identify those who are unlikely to derive long-term benefit from ruxolitinib and could be considered for alternative therapies. | Image credit: mdaros - stock.adobe.com
Refined iRR6 Model Improves Risk Stratification in Intermediate-1 Myelofibrosis

September 12th 2025

The study adds important data about how people with hematologic malignancies are affected by COVID-19 infection. | Image credit: Tyler Olson -stock.adobe.com
COVID-19 Risk Remains High for Patients With Hematologic Malignancies

September 10th 2025

While immunogenicity is often reduced, vaccination remains indispensable in multiple myeloma, according to the review. | Image credit: alernon77 - stock.adobe.com
Vaccination Remains Essential in Multiple Myeloma Despite Impaired Responses

September 4th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Lenalidomide Beats Standard of Care in Smoldering MM
May 23rd 2019

Lenalidomide Beats Standard of Care in Smoldering MM

Samantha DiGrande
As a precursor to myeloma, smoldering multiple myeloma (MM) currently has no treatment. In fact, the standard of care is observation until the patient starts to present with symptoms. However, according to new research that will be presented at the American Society of Clinical Oncology’s annual meeting in Chicago, Illinois, held May 31 to June 4, early treatment of smoldering MM may delay progression to full-blown disease.
Venetoclax Gains FDA Approval for Previously Untreated CLL, SLL
May 16th 2019

Venetoclax Gains FDA Approval for Previously Untreated CLL, SLL

Jaime Rosenberg
Venetoclax (Venclexta) has received FDA approval in combination with obinutuzumab (Gazyva) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), offering a chemotherapy-free regimen for patients with previously untreated disease.
Finding the Trigger That Sets Off Growth of Hodgkin Lymphoma Cells
May 16th 2019

Finding the Trigger That Sets Off Growth of Hodgkin Lymphoma Cells

Mary Caffrey
Cure rates for Hodgkin lymphoma are high, but survivors may live for decades with side effects from chemotherapy. Finding a new treatment target could lead to fewer toxic effects.
Study Identifies New Therapy Target For Blood Cancers in Mitochondria of Cancer Cells
May 11th 2019

Study Identifies New Therapy Target For Blood Cancers in Mitochondria of Cancer Cells

Jaime Rosenberg
Researchers have identified a new target in the mitochondria of cancer cells that indicate the potential of a treatment class for certain blood cancers.
Triple-Therapy Combo Without Chemo to Be Studied in DLBCL
May 10th 2019

Triple-Therapy Combo Without Chemo to Be Studied in DLBCL

Mary Caffrey
Proof-of-concept studies suggest the treatment that targets CD47 produces a strong response in patients with diffuse large B-cell lymphoma (DLBCL) with fewer adverse effects than current options.
IgL Translocation May Predict Poor Outcomes in Multiple Myeloma
May 2nd 2019

IgL Translocation May Predict Poor Outcomes in Multiple Myeloma

Jaime Rosenberg
DNA rearrangement may be the key to predicting poor outcomes in high-risk patients with multiple myeloma, according to a new study.
Chemo, Then Radiotherapy, May Boost Survival for Patients With Advanced Hodgkin Lymphoma
May 2nd 2019

Chemo, Then Radiotherapy, May Boost Survival for Patients With Advanced Hodgkin Lymphoma

Mary Caffrey
Radiotherapy after chemotherapy is controversial, as evidenced by the fact that doctors for some patients in the study did not follow the protocol for those assigned to radiotherapy and may have affected the results.
A Slower, Gentler CAR T-Cell Therapy? USC Says a Small Study Shows It Could Work
April 25th 2019

A Slower, Gentler CAR T-Cell Therapy? USC Says a Small Study Shows It Could Work

Mary Caffrey
Modifications to the engineering of the chimeric antigen receptor (CAR) mean that the patient produces fewer cytokines and has time to clear them before they build up in the bloodstream.
CMS Proposes Increased Reimbursement for CAR T-Cell Therapy, Price Hikes for Rural Hospitals
April 24th 2019

CMS Proposes Increased Reimbursement for CAR T-Cell Therapy, Price Hikes for Rural Hospitals

Jaime Rosenberg
As part of CMS’ FY 2020 Medicare Hospital Inpatient Prospective Payment System and Long-Term Acute Care Hospital Prospective Payment System Proposed Rule and Request for Information, the agency is proposing an increase in how much it reimburses hospitals for chimeric antigen receptor (CAR) T-cell therapy, as well as wage index hikes for rural hospitals.
Foundation Launches Investment Fund to Speed Multiple Myeloma Treatments
April 16th 2019

Foundation Launches Investment Fund to Speed Multiple Myeloma Treatments

AJMC Staff
The investment fund spun off from the Multiple Myeloma Research Foundation will start at $50 million and will be self-sustaining, focusing on early-stage biotech companies.
Peripheral Neuropathy Significantly Adds to Cost Burden of Multiple Myeloma
April 16th 2019

Peripheral Neuropathy Significantly Adds to Cost Burden of Multiple Myeloma

Jaime Rosenberg
Among patients with multiple myeloma treated with older proteasome inhibitors, those who developed peripheral neuropathy (PN) had significantly higher costs, suggesting that newer therapies may maintain effective treatment while lowering the economic and disease burden of PN in these patients.
Experimental Cancer Vaccine Shrinks Tumors in Form of Non-Hodgkin Lymphoma
April 13th 2019

Experimental Cancer Vaccine Shrinks Tumors in Form of Non-Hodgkin Lymphoma

Mary Caffrey
A preliminary study discussed how a vaccine regimen stimulated dendritic cells to attack tumors, which could point to a new way of making immunotherapy effective in cancers that have proved resistant to treatment thus far.
Carfilzomib Regimen Safe, Effective in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
April 11th 2019

Carfilzomib Regimen Safe, Effective in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

Jaime Rosenberg
Assessing 4 dose levels of carfilzomib, researchers have determined that the drug, in combination with thalidomide and low-dose dexamethasone, is highly safe and effective in transplant-eligible patients with newly diagnosed multiple myeloma.
Site Logo
April 6th 2019

Step Therapy in Medicare Advantage Hurts Patients, Providers, Says Schwartzberg

Mary Caffrey
Step therapy, which requires that patients try the payer’s preferred treatment before the one a physician recommends, is harmful to both sides of the doctor-patient relationship, according to Lee B. Schwartzberg, MD, medical director of the West Cancer and Research Institute, who spoke at the 2019 Community Oncology Conference, held in Orlando, Florida.
Study Identifies High Rates of Adherence to IMIDs Among Patients With Multiple Myeloma
April 6th 2019

Study Identifies High Rates of Adherence to IMIDs Among Patients With Multiple Myeloma

Jaime Rosenberg
A study of patients with multiple myeloma in a real-world setting found that adherence to immunomodulatory drugs (IMIDs) is high across all 3 options of the drugs.
Genomic Analysis of High-Risk Leukemia Finds Nearly Half of Cases May Respond to Precision Therapy
March 30th 2019

Genomic Analysis of High-Risk Leukemia Finds Nearly Half of Cases May Respond to Precision Therapy

Mary Caffrey
A comprehensive genomic analysis of acute erythoid leukemia (AEL) found that 45% of patients had mutations in signaling pathways that drive uncontrolled cell growth, and evidence shows these leukemias may respond to existing precision treatments.
Patient Preferences Should Be Considered for Treatment of Relapsed or Refractory Multiple Myeloma
March 30th 2019

Patient Preferences Should Be Considered for Treatment of Relapsed or Refractory Multiple Myeloma

Jaime Rosenberg
A study consisting of interviews and focus groups among patients with relapsed or refractory multiple myeloma brought attention to what patients value about their treatment.
FDA Stops Enrollment in Phase 3 MM Trial Due to 2-Fold Increase in Mortality
March 22nd 2019

FDA Stops Enrollment in Phase 3 MM Trial Due to 2-Fold Increase in Mortality

Samantha DiGrande
This week, the FDA sent out an alert to various healthcare professionals and the public to warn about the risks associated with the investigational use of venetoclax (Venclexta) for the treatment of patients with multiple myeloma (MM). The alert is based on data from the ongoing phase 3 BELLINI trial evaluating the drug for this treatment.
Site Logo
March 21st 2019

NCCN Panel Digs Into Reality of CAR T-Cell Reimbursement

Mary Caffrey
A panel during the opening day of the 2019 National Comprehensive Cancer Network Annual Conference examined the recent process for National Coverage Determination for chimeric antigen receptor (CAR) T-cell therapy and what it means for the future of innovative treatments.
Will CMS' CAR T-Cell Therapy Payment Plan Leave Out Community Practices?
March 14th 2019

Will CMS' CAR T-Cell Therapy Payment Plan Leave Out Community Practices?

Mary Caffrey
There is concern among stakeholder groups that references to “hospital” could mean that community practices would be unable to be reimbursed by Medicare under a proposed National Coverage Determination.
Once-Weekly Carfilzomib as Safe, Effective as Twice-Weekly Treatment in Newly Diagnosed MM
March 13th 2019

Once-Weekly Carfilzomib as Safe, Effective as Twice-Weekly Treatment in Newly Diagnosed MM

Jaime Rosenberg
Pooled data from 2 studies revealed that once-weekly administration of 70 mg/m2 of carfilzomib is as safe and effective in newly diagnosed multiple myeloma (MM) as twice-weekly administration of 36 mg/m2 of the treatment while also providing a more convenient treatment schedule.
Addressing Disparities in End-of-Life Care in Blood Cancers
March 8th 2019

Addressing Disparities in End-of-Life Care in Blood Cancers

Laura Joszt, MA
While use of palliative care at the end of life has increased, disparities remain, and not all patients who are terminally ill with blood cancers are having discussions about their goals of care at the end of life.
Carfilzomib Regimen Results in Longer Time to Next Treatment, Improved Survival in RRMM
March 6th 2019

Carfilzomib Regimen Results in Longer Time to Next Treatment, Improved Survival in RRMM

Jaime Rosenberg
Compared with other drug regimens, a carfilzomib-based regimen resulted in longer time to next treatment, as well as longer overall survival and improved 24-month survival, among patients with relapsed or refractory multiple myeloma (RRMM).
Patients With RRMM Are Undertreated With Carfilzomib in the Real World, Study Finds
March 2nd 2019

Patients With RRMM Are Undertreated With Carfilzomib in the Real World, Study Finds

Laura Joszt, MA
Since carfilzomib was approved at a 27 mg/m2 twice-weekly dose, it has since been optimized at 56 mg/m2 twice-weekly and a recent study found benefits of a 70 mg/m2 once-weekly dose. However, most patients are still treated with the original approval dosage, suggesting they might be undertreated.
Palliative Care, Hospice Improves End-of-Life Care Among Patients With Hematologic Malignancies
February 23rd 2019

Palliative Care, Hospice Improves End-of-Life Care Among Patients With Hematologic Malignancies

Jaime Rosenberg
Patients with hematologic malignancies often receive intensive care at the end of life (EOL), but new research has demonstrated that hospice services and palliative care are associated with significantly improved EOL care quality.
Once-Weekly Carfilzomib Safe, Effective in All Age Groups of Patients With RRMM
February 20th 2019

Once-Weekly Carfilzomib Safe, Effective in All Age Groups of Patients With RRMM

Laura Joszt, MA
Patients of all ages see benefits with once-weekly carfilzomib compared with a twice-weekly dose, according to an analysis of the phase 3 A.R.R.O.W. trial.
CMS Proposes That Patients Be Enrolled in Studies to Get Coverage for CAR T-Cell Therapy
February 15th 2019

CMS Proposes That Patients Be Enrolled in Studies to Get Coverage for CAR T-Cell Therapy

Mary Caffrey Allison Inserro
The payment model will gather data that will be used to create a long-term model for patients not enrolled in studies or registries.
Preparing Patients and the Health System for Curative Therapies in the Pipeline
February 12th 2019

Preparing Patients and the Health System for Curative Therapies in the Pipeline

Laura Joszt, MA
Experts at the “Paying for Cures: Ensuring patient access and system sustainability" event discussed how the healthcare system can pay for curative therapies that have high upfront costs with benefits that accrue over time.
Identifying Patient Preferences in MM Treatment Improves Shared Decision Making
February 10th 2019

Identifying Patient Preferences in MM Treatment Improves Shared Decision Making

Laura Joszt, MA
Two studies presented at the 60th American Society of Hematology Annual Meeting and Exposition examined patient preferences in multiple myeloma (MM) treatment and the importance of understanding these preferences when making treatment decisions.
Ineligibility for Intensive Chemotherapy Impacts QoL Scores, Survival in AML
February 7th 2019

Ineligibility for Intensive Chemotherapy Impacts QoL Scores, Survival in AML

David Bai, PharmD
Patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy tend to have poor health-related quality of life (HRQoL) scores that are independent predictors of poor survival, a recent study reported.
<1
...
141516171819202122
...
29>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo